InvestorsHub Logo
Followers 20
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Friday, 02/19/2021 4:22:59 PM

Friday, February 19, 2021 4:22:59 PM

Post# of 152
Immunic updates make shares even more attractive, says Roth Capital
Roth Capital analyst Zegbeh Jallah keeps a Buy rating on Immunic with a $64 price target after the company presented detailed topline results from its Phase 2 CALVID-1 study of IMU-838 in hospitalized patients with moderate COVID-19 and new data for its Phase 2 investigator-sponsored study of IMU-838 in patients with primary sclerosing cholangitis. Both datasets are "supportive of continued development," Jallah tells investors in a research note. The analyst says that neither program is included in her model, creating "even more upside potential," in addition to a pipeline "that remains significantly undervalued."'
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMUX News